See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Atlas Venture is a leading early-stage biotech venture capital firm that has been building breakthrough biotechnology companies for over 30 years. The firm employs a seed-led venture creation strategy, working shoulder-to-shoulder with exceptional scientists and entrepreneurs to translate high-impact science into life-changing medicines for patients. Atlas operates a two-fund model: an early-stage fund (Fund XIV, $450M) to found, seed, incubate, and invest in new biotech startups, and a complementary Opportunity Fund ($400M) for continued investment in later-stage private and public financings of portfolio companies. The firm's approach is characterized by a collaborative, science-first, patient-centric culture spanning disease areas including gene therapy, precision oncology, RNA biology, and immunology, with a disciplined focus on building scalable businesses that deliver both patient impact and superior investment returns.
Notable quotes
“Core to Atlas is a disciplined approach to our firm, funds, and portfolio. We believe deeply in the power of a focused venture creation strategy, building biotech companies across the spectrum of disease areas, modalities, and business models.”
“If we can positively impact the lives of patients by discovering and developing an innovative new medicine, the system will reward that risk-taking with superlative investment returns.”
“I am immensely proud of the organization Atlas Venture has become. I look forward to continuing to work alongside my partners, countless talented entrepreneurs, and the broader biopharma community toward our shared goal of bringing groundbreaking medicines forward.”
Team
Kevin Bitterman
Partner
Michael Gladstone
Partner
Jason Rhodes
Partner
David Grayzel
Partner
Aimee Raleigh
Principal
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Kailera Therapeutics | Series A | $400m | 2024-10-01 |
| Ethyreal | Series A | $101m | 2025-01-01 |
| Renasant Bio | Seed | $55m | 2025-07-10 |
| GRO Biosciences | Series B | $60m | 2024-07-19 |
| Dyne Therapeutics | Seed | — | 2019-01-01 |
| Kymera Therapeutics | Seed | — | 2016-01-01 |
| Disc Medicine | Seed | — | 2018-01-01 |
| Accent Therapeutics | Seed | — | 2019-01-01 |
| Affinia Therapeutics | Seed | — | 2020-01-01 |
| HotSpot Therapeutics | Seed | — | 2018-01-01 |
Frequent co-investors
Fit check
Is Atlas Venture a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit